EASL Podcasts

The treatment of liver cirrhosis – currently based on symptomatic management of complications – has barely changed in last 20 years. In this episode, the experts discuss the use of statins, for which there is growing body of evidence of their beneficial effects in patients suffering with cirrhosis. Faculty This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme. Related episodes Liver cirrhosis in 2023: Unmet needs and how to address themAlbumin in Cirrhosis: For all, some, or none?JHEP Live: is the term ‘decompensated cirrhosis’ outdated?Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies withinAll EASL Studio Podcasts are available on EASL Campus.

In this episode, participants tackle the relationship between metabolic dysfunction-associated steatotic liver diseases (MASLD) and type 2 diabetes (T2D), exploring their prevalence and the potential for more aggressive outcomes. Experts weigh in on the pressing questions of whether non-invasive test thresholds should be adapted for MASLD patients with T2D and which drugs should take precedence as first-line treatments for high-risk MASLD cases. Faculty This episode is scheduled according to the international calendar for the World Diabetes Day (14 November). This EASL Studio is supported by Boehringer Ingelheim and Novo Nordisk. EASL has received no input from Boehringer Ingelheim or Novo Nordisk with regards to the content of this programme. Related episodes: Bugs and the liver — the role of the gut microbiome in liver diseasesFats or carbs, who is the real villain?All EASL Studio Podcasts are available on EASL Campus.

In honour of the Awareness Week on Alcohol related harm (21 November – 1 December), this episode discussed how the new nomenclature will affect healthcare pathways for those suffering with Alcohol-related liver diseases. Faculty Related episodes: Steatotic liver disease global consensus to change nomenclatureThe central role of alcohol and food policies on liver healthJHEP Live: Stigma and alcoholAll EASL Studio Podcasts are available on EASL Campus.

Join the faculty as they take a deep dive into hepatitis delta (HDV) to: Faculty Related episodes: Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitorTreatment of HBV-HDV coinfection in the era of entry inhibitionAll EASL Studio Podcasts are available on EASL Campus.

During this episode, the experts discuss of what it really takes to implement a successful lifestyle modification in behavioural therapy. Tune in to learn tools and tips that can help treat patients in improving their liver health and quality of life. This episode was scheduled according to the international calendar for the World Food Day (16 October) Faculty Related episodes The central role of alcohol and food policies on liver healthFats or carbs, who is the real villain?All EASL Studio Podcasts are available on EASL Campus.

This episode delves into the pervasive yet seldom-discussed issue of burnout, particularly prevalent in high-pressure fields like clinical medicine and competitive research. Fuelled by relentless ambition and a fear of falling short, professionals push themselves to the limit, often neglecting their own well-being. As the world grapples with a confluence of challenges including the ongoing pandemic, climate crisis, and geopolitical tensions, the need for self-care becomes more pressing than ever. Faculty Related Nature article by participant Kelly Korreck: How I managed my intense burnout This episode is scheduled according to the international calendar for the World Mental Health Day (10 October). All EASL Studio Podcasts are available on EASL Campus.

In this episode, the discussants examines the following questions, raised after a Journal of Hepatology’s nomenclature article: Faculty Related article A multi-society Delphi consensus statement on new fatty liver disease nomenclatureRelated episodes Steatotic liver disease global consensus to change nomenclatureAll EASL Studio Podcasts are available on EASL Campus.

This EASL Studio episode covers the highlights of the SLD Summit 2023, including: Faculty Related episodes Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysSteatotic liver disease global consensus to change nomenclatureThe conundrum of NASH: The growing global disease burden with low disease awarenessJHEP Live: New and promising drugs for NASH on the horizonAll EASL Studio Podcasts are available on EASL Campus.

Hepatitis E is an inflammation of the liver caused by infection with the hepatitis E virus (HEV). HEV infections are among the most common causes of acute hepatitis worldwide. 2 different settings: This Studio focuses on Zoonotic Hep E, especially HEV Genotype 3 infection and discusses recent highlights as well as current challenges in basic, translational, and clinical research on Hepatitis E. Learn more about the viral and host determinants for the diverse clinical outcomes of HEV genotype 3 infections, the challenge of chronic Hepatitis E in immunocompromised patients, as well as the current state of vaccine development and other preventive measures. Faculty All EASL Studio Podcasts are available on EASL Campus.

Thirty percent of the global population have too much fat in their liver. The big question is: are they really sick when most will not end up with liver disease? This episode discusses: Faculty Related episode Steatotic liver disease global consensus to change nomenclatureAll EASL Studio Podcasts are available on EASL Campus.

This #EASLStudio JHEP Live discusses the newly released EASL Clinical Practice Guidelines on Acute-on-chronic liver failure (ACLF). In particular: Faculty All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and is presenting the work of international liver societies to beat liver diseases. Faculty All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and is covering practice changing following data presented during the congress. Faculty All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and discusses the nomenclature change for steatotic liver disease. Faculty All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Midday Talks was live broadcast during the EASL Congress 2023 and discusses the newly released EASL policy statement on alcohol harm and related liver diseases. The document aims to highlight the extensive harm resulting from alcohol consumption and shine a light on the effective, yet underused, harm reduction policies available to European countries. Faculty All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Good Morning Vienna was live broadcast during the EASL Congress 2023 and is presenting the highlights of liver cancer research at the congress. Faculty All EASL Studio Podcasts are available on EASL Campus.

This EASL Studio Closing was live broadcast during the EASL Congress 2023 and discusses the future of hepatology. Faculty All EASL Studio Podcasts are available on EASL Campus.

In honour of International NASH Day, the final episode of EASL Studio season 4 is shedding light on non-alcoholic steatohepatitis (NASH), a disease with increasing global prevalence but low awareness. Faculty All EASL Studio Podcasts are available on EASL Campus.

Non-alcoholic steatohepatitis (NASH) is rapidly emerging as a leading cause of chronic liver disease, presenting significant challenge due to the limited treatment options available. This EASL Studio JHEP Live aims to explore novel and promising treatments currently being evaluated for the treatment of NASH. In particular: Faculty Related articles A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitisEvaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomizedplacebo-controlled trial (DESTINY-1)Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASHAll EASL Studio Podcasts are available on EASL Campus.

Clinical evidence indicates that cigarette smoking negatively impacts the incidence and severity of fatty liver disease, fibrosis progression, hepatocellular carcinoma development, and the outcomes of patients with advanced liver disease. The underlying mechanisms are complex and involve different pathophysiological pathways including oxidative stress and oncogenic signals. To coincide with World No Tobacco Day, 31 May, this EASL Studio discusses some of the pathophysiological mechanisms that drive the progression of liver disease and cancer risk in those who smoke. Faculty All EASL Studio Podcasts are available on EASL Campus.